FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Biehl James		 2. Issuer Name and Ticker or Trading Symbol

TYME TECHNOLOGIES, INC. [ TYME ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Legal Officer
(Last)          (First)          (Middle)

C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103		 3. Date of Earliest Transaction (MM/DD/YYYY)

9/16/2022
(Street)

BEDMINSTER, NJ 07921
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/16/2022  D  105000 D (1)0 D  
Common Stock 9/16/2022  D  150 D (2)0 I See Footnote (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option - Option to buy $2.42 9/16/2022  D     500000   (4)9/8/2028 Common Stock 500000  (4)0 D  
Employee Stock Option - Option to buy $1.56 9/16/2022  D     253200   (5)5/2/2029 Common Stock 253200  (5)0 D  
Employee Stock Option - Option to buy $1.39 9/16/2022  D     360000   (6)5/6/2030 Common Stock 360000  (6)0 D  
Employee Stock Option - Option to buy $1.43 9/16/2022  D     500000   (7)6/13/2031 Common Stock 500000  (7)0 D  
Employee Stock Option - Option to buy $0.32 9/16/2022  D     482200   (8)4/21/2032 Common Stock 482200  (8)0 D  
Employee Stock Option - Option to buy $2.95 9/16/2022  D     12500   (9)3/28/2027 Common Stock 12500  (9)0 D  
Employee Stock Option - Option to buy $2.95 9/16/2022  D     12500   (10)3/28/2027 Common Stock 12500  (10)0 D  
Employee Stock Option - Option to buy $2.90 9/16/2022  D     75000   (11)5/24/2028 Common Stock 75000  (11)0 D  
Explanation of Responses:
(1) Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,601 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
(2) Disposed of pursuant to the merger agreement between the issuer and Syros in exchange for 6 shares of Syros common stock after giving effect to the Reverse Split, with cash paid in lieu of fractional shares.
(3) 150 shares are owned by Mr. Biehl's spouse.
(4) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $55.23 per share, after giving effect to the Reverse Split.
(5) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,095 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
(6) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 15,775 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
(7) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
(8) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.
(9) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
(10) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
(11) This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Biehl James
C/O TYME TECHNOLOGIES, INC.
1 PLUCKEMIN WAY - SUITE 103
BEDMINSTER, NJ 07921

Chief Legal Officer
Signatures
By: /s/ Richard Cunningham as attorney-in-fact for James Biehl9/16/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Tyme Technologies Charts.
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Tyme Technologies Charts.